Nations Financial Group Inc. IA ADV Buys 1,214 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Nations Financial Group Inc. IA ADV raised its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 12.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,226 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,214 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Collegium Pharmaceutical were worth $434,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Caxton Associates LP acquired a new position in Collegium Pharmaceutical in the 1st quarter valued at $1,730,000. Foundry Partners LLC bought a new stake in Collegium Pharmaceutical during the second quarter valued at about $492,000. O Shaughnessy Asset Management LLC grew its position in shares of Collegium Pharmaceutical by 159.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after purchasing an additional 28,100 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Collegium Pharmaceutical by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after purchasing an additional 17,942 shares during the period. Finally, Squarepoint Ops LLC lifted its position in shares of Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock worth $3,553,000 after purchasing an additional 72,874 shares during the last quarter.

Collegium Pharmaceutical Trading Down 3.9 %

Shares of Collegium Pharmaceutical stock opened at $30.18 on Thursday. Collegium Pharmaceutical, Inc. has a 52-week low of $24.61 and a 52-week high of $42.29. The firm has a market capitalization of $973.31 million, a PE ratio of 13.01 and a beta of 0.95. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company’s fifty day moving average price is $36.66 and its two-hundred day moving average price is $35.11.

Analysts Set New Price Targets

COLL has been the subject of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Finally, Truist Financial increased their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.